Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using.

Slides:

Advertisements

Similar presentations

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Advertisements

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

BV6 increases tumor burden in bone.

Validation of St6GalNAc2 as a metastasis suppressor gene.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

coTCRcys-transduced T cells control tumor growth in vivo.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

In vivo thrombosis of tumor vasculature.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Matriptase-2 inhibited breast tumor development in vivo.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Fig. 5 In vivo gene delivery by the T4-AAV nanoparticles.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

A, inhibition of FGF2 binding to the FGFR by porphyrin analogues.

HMQ1611 inhibited breast tumor growth in mice.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Effect of CDV on human SF7796 xenografts in vivo.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

PK profile of OTL78. PK profile of OTL78. A, Representative time-dependent whole-body fluorescence images over white light images of a mouse bearing 22Rv1.

Whole-mount analysis of tumor induced lymphatic sprouting by confocal microscopy. Whole-mount analysis of tumor induced lymphatic sprouting by confocal.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Hypoxic Ag-specific CD8+ T cells are less functional and less proliferative. Hypoxic Ag-specific CD8+ T cells are less functional and less proliferative.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Change in FES uptake in the tumor during fulvestrant treatment.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Imaging inflammation and tumor-associated lymphangiogenesis.

SPARC is required for spontaneous metastasis

Pdcd4 delays and attenuates papilloma development in a dose-dependent manner. Pdcd4 delays and attenuates papilloma development in a dose-dependent manner.

A, VEGFR2 staining in the tumor rim and center.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

PDL192 and inhibit the growth of xenograft tumors.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.

Effects of ZOL treatment on pulmonary metastases.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

Presentation transcript:

Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. A, plotting of the serum concentration of VEGFR-3-Ig in mice receiving different doses of AdVEGFR-3-Ig (1.0e+9 pfu: 442.54 ± 55.21 μg/mL, n = 11; 1.2e+8 pfu: 119.27 ± 46.89 μg/mL, n = 7; 1.5e+7 pfu: 28.83 ± 3.17 μg/mL, n = 6; and 2.0e+6 pfu: 4.67 ± 1.77 μg/mL, n = 5). B, bioluminescent signals emitted from the lymph nodes of mice treated with different doses of AdVEGFR-3-Ig or AdLacZ (1.0e+9 pfu) were quantified as photons per second per square centimeter per steradian [× 107, mean ± SD; 0.30 ± 0.46 (n = 6), 0.18 ± 0.29 (n = 6), 2.05 ± 4.90 (n = 6), 3.21 ± 4.26 (n = 5), and 18.10 ± 19.90 (n = 6), respectively]. C-F, representative images of axillary lymph nodes (dotted circles) from the mice treated with AdVEGFR-3-Ig (1.0e+9 pfu). Note that micrometastasis to axillary lymph nodes as determined by the presence of bioluminescent signals occurred also in some of the treated mice (D-F). G, images of axillary lymph nodes from tumor-bearing mice receiving AdLacZ and AdR3-Ig (W2 and W3, primary tumors removed at week 2 or 3). Tumor metastasis to lymph nodes was not observed in the mice treated with AdR3-Ig when the primary tumors were surgically removed within 3 weeks. Yulong He et al. Cancer Res 2005;65:4739-4746 ©2005 by American Association for Cancer Research